Bibliography
- DIBB NJ, DILWORTH SM, MOL CD: Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nature Rev. (2004) 4:718-727.
- DAVIES H, BIGNELL GR, COX C et al.: Mutations of the BRAF gene in human cancer. Nature (2002) 417:949-954.
- STRUMBERG D, SEEBER S: Raf kinase inhibitors in Oncology. Onkologie (2005) 28:101-107.
- THOMPSON N, LYONS J: Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr. Opin. Pharm. (2005) 5(4):350-356.
- HALL-JACKSON CA, EYERS PA, COHEN P et al.: Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. (1999) 6:559-568.
- TAKLE AK, BROWN MJB, DAVIES S et al.: The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg. Med. Chem. Lett. (2006) 16:378-381.
- RINI BI: Sorafenib. Expert Opin. Pharmacother. (2006) 7(4):453-461.
- BEERAM M, PATNAIK A, ROWINSKY EK: Raf: a strategic target for therapeutic development against cancer. J. Clin. Oncol. (2005) 23:6771-6790.
- BROWN DS, BELFIELD AJ, BROWN GR et al.: A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. Bioorg. Med. Chem. Lett. (2004) 14:5383-5387.
Patents
- ZENECA LTD: WO9822103 (1998).
- ZENECA LTD: WO999915164 (1999).
- ZENECA LTD: WO9959959 (1999).
- ZENECA LTD: WO0007991 (2000).
- ZENECA LTD: WO0018738 (2000).
- ASTRAZENECA AB: WO00055153 (2000).
- ASTRAZENECA AB: WO05123696 (2005).
- ASTRAZENECA UK LTD: WO06024834 (2006).
- ASTRAZENECA UK LTD: WO06024836 (2006).